Pharmaron Proposes 2026 H-Share Incentive Scheme for Long-Term Growth

Stock News07-24 18:38

Pharmaron (03759) has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility.

The company's board has resolved and approved the adoption of the 2026 H-Share Award Plan, with a plan limit set at 28 million H-shares. The share source for the plan includes treasury H-shares repurchased by the company from time to time, as well as newly issued H-shares. The primary objective is to fully mobilize employee initiative and creativity, effectively enhance core team cohesion and corporate competitiveness, and promote the company's sustained, stable, and high-quality development.

The 2026 H-Share Award Plan is expected to be effective for a period of 10 years from its adoption date. Its terms will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The plan will only take effect after it is approved by a resolution of the company's shareholders.

To facilitate the implementation of the 2026 H-Share Award Plan, the board will also propose granting a share repurchase authorization to the shareholders. This authorization will be used, among other purposes, to execute the 2026 H-Share Award Plan, and to authorize the board and its delegates to manage the plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170629012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170629012","market":"hk","top_or_hot":-1,"title":"Pharmaron Proposes 2026 H-Share Incentive Scheme for Long-Term Growth","media":"Stock News","content":"<p><b>Pharmaron (03759)</b> has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility. <br><br>\nThe company's board has resolved and approved the adoption of the 2026 H-Share Award Plan, with a plan limit set at 28 million H-shares. The share source for the plan includes treasury H-shares repurchased by the company from time to time, as well as newly issued H-shares. The primary objective is to fully mobilize employee initiative and creativity, effectively enhance core team cohesion and corporate competitiveness, and promote the company's sustained, stable, and high-quality development. <br><br>\nThe 2026 H-Share Award Plan is expected to be effective for a period of 10 years from its adoption date. Its terms will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The plan will only take effect after it is approved by a resolution of the company's shareholders. <br><br>\nTo facilitate the implementation of the 2026 H-Share Award Plan, the board will also propose granting a share repurchase authorization to the shareholders. This authorization will be used, among other purposes, to execute the 2026 H-Share Award Plan, and to authorize the board and its delegates to manage the plan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Proposes 2026 H-Share Incentive Scheme for Long-Term Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Proposes 2026 H-Share Incentive Scheme for Long-Term Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-24 18:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pharmaron (03759)</b> has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility. <br><br>\nThe company's board has resolved and approved the adoption of the 2026 H-Share Award Plan, with a plan limit set at 28 million H-shares. The share source for the plan includes treasury H-shares repurchased by the company from time to time, as well as newly issued H-shares. The primary objective is to fully mobilize employee initiative and creativity, effectively enhance core team cohesion and corporate competitiveness, and promote the company's sustained, stable, and high-quality development. <br><br>\nThe 2026 H-Share Award Plan is expected to be effective for a period of 10 years from its adoption date. Its terms will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The plan will only take effect after it is approved by a resolution of the company's shareholders. <br><br>\nTo facilitate the implementation of the 2026 H-Share Award Plan, the board will also propose granting a share repurchase authorization to the shareholders. This authorization will be used, among other purposes, to execute the 2026 H-Share Award Plan, and to authorize the board and its delegates to manage the plan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1170629012","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170629012","pubTimestamp":1784889497,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Pharmaron (03759) has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility.  The company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","03759":"康龙化成","BK0216":"研究试验","BK1141":"生命科学工具和服务","BK1576":"医药外包概念"},"translate_title":"康龙化成提出2026年长期增长H股激励计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":1,"03759":1},"content_text":"Pharmaron (03759) has announced a proposal to adopt a new H-share incentive plan for 2026, aiming to sustain its equity incentive mechanism with compliance and operational feasibility. \nThe company's board has resolved and approved the adoption of the 2026 H-Share Award Plan, with a plan limit set at 28 million H-shares. The share source for the plan includes treasury H-shares repurchased by the company from time to time, as well as newly issued H-shares. The primary objective is to fully mobilize employee initiative and creativity, effectively enhance core team cohesion and corporate competitiveness, and promote the company's sustained, stable, and high-quality development. \nThe 2026 H-Share Award Plan is expected to be effective for a period of 10 years from its adoption date. Its terms will comply with the requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The plan will only take effect after it is approved by a resolution of the company's shareholders. \nTo facilitate the implementation of the 2026 H-Share Award Plan, the board will also propose granting a share repurchase authorization to the shareholders. This authorization will be used, among other purposes, to execute the 2026 H-Share Award Plan, and to authorize the board and its delegates to manage the plan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170629012","isCrawlerRequest":true}